ArticleLung India : official organ of Indian Chest Society2026
Safety and outcome of bedaquiline and delamanid-based longer oral regimen in Indian children less than 5 years with drug-resistant tuberculosis.
Article in Lung India : official organ of Indian Chest Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPaediatric drug-resistant tuberculosis (DR-TB) remains a significant challenge, especially in high-burden countries like India. While bedaquiline (BDQ) and delamanid (DLM) are shown to be successful in treating multi-drug-resistant TB (MDR-TB) in older children, evidence of their safety and effectiveness in children under 5 is limited. We set out to evaluate the clinical outcomes and safety of BDQ and concurrent BDQ and DLM-based regimens in children under 5 years with DR-TB in a tertiary care Mumbai, India.
methodsA retrospective study was conducted on 23 children under 5 years diagnosed with DR-TB and treated with BDQ or BDQ and DLM-based longer oral regimens between December 2021 and May 2024. Data on treatment regimens, drug resistance patterns, adverse effects, and outcomes were collected. Treatment was stopped based on clinico-radiological response.
resultsAmong the 23 children, 8 (34.78%) completed treatment, 12 (52.17%) were still undergoing therapy, 1 (4.34%) was lost to follow-up, and 2 (8.69%) died. For those who completed treatment, the average duration of treatment was 19.25 months. Weight gain was observed in 19 (82.6%) patients. Adverse drug reactions were noted in 8 (34.78%) patients, of which 2 (25%) had vomiting, 2 (25%) had hallucinations, 1 (12.5%) had psychosis, 4 (50%) had anaemia, and 3 (37.5%) had QTcF prolongation while on treatment.
conclusionBDQ and DLM-based regimens appear effective and generally well tolerated in treating DR-TB in children under 5. However, a longer course of treatment of over 18 months is required. Careful monitoring for side effects, especially QTc prolongation, remains critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.